List of Excipients in Branded Drug ACIPHEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aytu Therapeutics LLC	ACIPHEX	rabeprazole sodium	23594-205	ALUMINUM OXIDE
Aytu Therapeutics LLC	ACIPHEX	rabeprazole sodium	23594-205	CARRAGEENAN
Aytu Therapeutics LLC	ACIPHEX	rabeprazole sodium	23594-205	DIACETYLATED MONOGLYCERIDES
Aytu Therapeutics LLC	ACIPHEX	rabeprazole sodium	23594-205	ETHYLCELLULOSES
Aytu Therapeutics LLC	ACIPHEX	rabeprazole sodium	23594-205	FD&C BLUE NO. 2

AcipHex Excipient Strategy and Commercial Opportunities for Rabeprazole

Last updated: September 2, 2026

AcipHex is the branded delayed-release formulation of rabeprazole sodium, a proton-pump inhibitor marketed by Eisai and previously commercialized with Janssen in the United States. The core drug and original formulation exclusivities have expired, leaving commercial opportunity in generic delayed-release tablets, pediatric sprinkle products, alternative delivery systems, and excipient-driven product differentiation.

The strongest opportunities are not in copying the historical AcipHex tablet alone. They are in improving acid protection, reducing manufacturing complexity, expanding pediatric and geriatric usability, and creating differentiated rabeprazole products that fit FDA 505(b)(2) or ANDA pathways.

What is AcipHex and which rabeprazole products are commercially relevant?

AcipHex contains rabeprazole sodium, a proton-pump inhibitor approved for gastroesophageal reflux disease, duodenal ulcer, gastric ulcer, Helicobacter pylori eradication regimens, and other acid-related conditions. The drug is administered as an enteric-coated delayed-release product because rabeprazole is acid labile.

Product	Active ingredient	Dosage form	Primary excipient challenge	Commercial status
AcipHex delayed-release tablet	Rabeprazole sodium	Enteric-coated tablet	Protection from gastric acid and moisture	Branded product with generic competition
AcipHex Sprinkle	Rabeprazole sodium	Delayed-release capsule containing enteric-coated granules	Sprinkle stability, dose uniformity, acid resistance	Pediatric and swallowing-disorder opportunity
Generic rabeprazole DR	Rabeprazole sodium	Delayed-release tablet or capsule	Bioequivalence and formulation robustness	Established generic category
Potential 505(b)(2) rabeprazole	Rabeprazole sodium	ODT, liquid, suspension, multiparticulate or other delivery system	Clinical bridging and differentiated performance	Commercial development opportunity

FDA approved AcipHex delayed-release tablets in 1997. AcipHex Sprinkle received FDA approval in 2016 for pediatric patients who can swallow soft foods but cannot swallow tablets.[1,2]

What excipients are used in AcipHex delayed-release tablets?

The AcipHex tablet uses a conventional acid-labile drug protection strategy. The core contains alkaline and hydrophilic excipients, while the dosage form uses an enteric coating to delay release until the product reaches the higher-pH environment of the intestine.

Public labeling identifies excipient classes associated with the tablet, including:

• Mannitol as a water-soluble diluent.
• Magnesium oxide as an alkalizing agent and stabilizing component.
• Low-substituted hydroxypropyl cellulose as a disintegrant or matrix-modifying excipient.
• Hydroxypropyl cellulose as a binder.
• Magnesium stearate as a lubricant.
• Ethylcellulose and hypromellose phthalate in coating-related functions.
• Talc, titanium dioxide and iron oxide pigments in the coating system.
• Dibutyl sebacate or a comparable plasticizing component in the enteric coating system, depending on the referenced product presentation and market label.[1]

The strategic function of the excipient system is more important than the individual ingredients. Rabeprazole products need:

1. An alkaline microenvironment to limit degradation.
2. Adequate mechanical strength during compression and coating.
3. Low moisture exposure during manufacture and storage.
4. A reliable enteric coating that resists gastric fluid.
5. Rapid release after transition to intestinal pH.
6. Uniform drug distribution at low dose strengths.

Why magnesium oxide matters in rabeprazole formulations

Magnesium oxide can provide alkalinity inside the dosage form. For acid-labile proton-pump inhibitors, an alkaline stabilizer can reduce degradation during granulation, compression, coating and storage.

The commercial tradeoff is process variability. Magnesium oxide differs by particle size, surface area, purity, bulk density and reactivity. These properties affect:

• Blend uniformity.
• Tablet hardness.
• Disintegration time.
• Moisture sensitivity.
• Dissolution after enteric-coating rupture.
• Stability under accelerated conditions.

A generic manufacturer that changes magnesium oxide grade may need to control the excipient through tighter material specifications rather than relying only on nominal chemical identity.

Why enteric polymers create formulation value

The enteric coating is the principal release-control component. Hypromellose phthalate, methacrylic acid copolymers, cellulose acetate phthalate and polyvinyl acetate phthalate can provide comparable acid resistance, but they do not behave identically.

Key variables include:

Variable	Commercial impact
Polymer type	Controls pH threshold and release profile
Coating weight gain	Affects acid resistance, tablet size and cost
Plasticizer level	Affects flexibility, cracking and storage stability
Talc level	Affects anti-tacking properties and coating uniformity
Spray rate and inlet temperature	Affect coating defects and batch yield
Seal coat design	Controls moisture migration and drug-polymer interaction

An excipient strategy that reduces coating weight while maintaining acid resistance can lower cycle time and improve manufacturing economics. A more flexible polymer system can reduce cracking during packaging, transport and long-term storage.

What excipient strategy best supports generic AcipHex?

The lowest-risk strategy is an ANDA formulation that matches the reference product’s dosage form, strength, release mechanism and inactive-ingredient framework as closely as practical.

For a generic rabeprazole delayed-release tablet, the development program should prioritize:

• A stable alkaline core.
• Direct compression or low-moisture granulation.
• A reproducible enteric film.
• Low residual moisture.
• Comparable dissolution in acid and buffer stages.
• Compatibility with high-speed coating equipment.
• Tight control of magnesium oxide and enteric-polymer grades.
• Packaging that limits humidity exposure.

The formulation should avoid unnecessary excipient novelty. A new excipient or materially different inactive-ingredient system can increase FDA review complexity and may require additional justification. Under the FDA’s inactive-ingredient framework, a proposed generic generally benefits from using excipients already accepted for the same route and dosage form.[3]

Excipient risks in an ANDA

The main technical risks are not the identity of common excipients. They are the interaction between excipients and the active ingredient.

Important failure modes include:

• Rabeprazole degradation caused by acidic excipient impurities.
• Delayed release caused by excessive coating thickness.
• Premature release caused by coating porosity or cracking.
• Incomplete drug release after intestinal pH transition.
• Segregation of low-dose rabeprazole during blending.
• Magnesium oxide variability between suppliers.
• Moisture uptake through blister or bottle packaging.
• Dissolution drift after storage.
• Inconsistent granule size in sprinkle formulations.

The strongest generic development programs treat excipient controls as critical material attributes rather than as ordinary formulation inputs.

What formulations are protected by AcipHex-related patents?

The original AcipHex patent estate covered rabeprazole and pharmaceutical compositions rather than a durable monopoly over every use of standard excipients.

Historic patent categories

Patent category	Covered subject matter	Current commercial significance
Rabeprazole compound patents	Chemical compound and salts	Core exclusivity expired
Pharmaceutical composition patents	Rabeprazole-containing dosage forms	Historic barrier; expiration has removed the principal obstacle
Enteric dosage-form patents	Delayed-release tablets and coated particles	May affect formulation design if unexpired claims remain
Method-of-use patents	GERD, ulcer and H. pylori treatment	Most original rights are expired or commercially limited
Pediatric sprinkle patents	Granules, capsule presentation and pediatric administration	Relevant to differentiated formulation review
Manufacturing patents	Granulation, coating or stabilization processes	Potentially relevant to freedom-to-operate by product and jurisdiction

The precise patent position depends on the jurisdiction, claim scope, terminal disclaimers, patent-term adjustment, pediatric extensions and Orange Book listing history. The original U.S. rabeprazole exclusivity period has ended, and generic rabeprazole products are marketed in the United States.[1,4]

Routine use of mannitol, magnesium oxide, hydroxypropyl cellulose or an enteric polymer is unlikely by itself to create a strong proprietary position. Patent value is more likely to arise from a defined combination, particle architecture, coating process, stability result, dosing method or delivery system.

When did AcipHex lose exclusivity?

AcipHex lost its principal small-molecule exclusivity years ago. The original U.S. approval dates to 1997, and generic rabeprazole delayed-release products entered the market after the relevant patent and regulatory barriers were overcome.

Milestone	Date or status
Original AcipHex U.S. approval	1997
Original compound and product exclusivity	Expired
Generic rabeprazole availability	Established
AcipHex Sprinkle approval	2016
Current commercial focus	Generic supply, pediatric delivery and formulation differentiation

AcipHex Sprinkle has a separate product history from the original tablet. Its pediatric formulation and dosage presentation can create product-specific regulatory and formulation considerations even though the active ingredient itself is old.[2]

What is the Orange Book status of AcipHex?

The Orange Book identifies approved drug products, therapeutic-equivalence evaluations and patent or exclusivity information for listed reference products.[4]

For commercial diligence, the relevant questions are:

• Whether AcipHex or AcipHex Sprinkle remains listed as a reference product.
• Which strengths and dosage forms have active generic equivalents.
• Whether any patent information remains listed for the relevant product.
• Whether a generic applicant would need a Paragraph IV certification.
• Whether the proposed product is eligible for an ANDA or requires a 505(b)(2) application.

Because the original tablet has long-standing generic competition, a new manufacturer is more likely to face competition, pricing pressure and abbreviated regulatory requirements than a primary patent barrier. A differentiated product that changes the dosage form, route, release profile or patient population may fall outside a simple ANDA strategy.

Are Paragraph IV challenges still relevant for AcipHex?

Paragraph IV litigation is most relevant when an applicant challenges a listed patent as invalid, unenforceable or not infringed. For the original AcipHex tablet, the commercial importance of Paragraph IV challenges has declined because the core patents have expired and generic products are already marketed.

Paragraph IV risk can reappear if a later-listed patent covers:

• A new sprinkle formulation.
• A pediatric dosing method.
• A specific coating architecture.
• A defined stability-enhancing excipient combination.
• A novel administration method.
• A new combination product.

A generic applicant must assess product-specific Orange Book listings rather than assume that expiration of the original compound patent eliminates every possible patent issue.

What commercial opportunities exist in AcipHex excipients and formulations?

1. Lower-cost generic delayed-release tablets

The largest volume opportunity remains standard rabeprazole delayed-release tablets. Competitive advantage depends on:

• High coating throughput.
• Low reject rates.
• Reliable dissolution.
• Low-cost raw materials.
• Moisture-resistant packaging.
• Multiple approved suppliers for critical excipients.

A manufacturer with established enteric-coating capacity can compete on cost without developing a novel delivery system.

2. Pediatric and geriatric multiparticulates

AcipHex Sprinkle demonstrates a clear patient-need segment. Multiparticulate products can address:

• Children unable to swallow tablets.
• Adults with dysphagia.
• Patients receiving medicines through selected enteral feeding systems.
• Dose titration needs not served by fixed-strength tablets.

The key excipient opportunity is a neutral or mildly alkaline granule with a robust enteric film that can be dispersed over soft food without rapid drug release or unacceptable taste.

3. Orally disintegrating or rapidly dispersing rabeprazole

An orally disintegrating product could improve administration for patients who cannot swallow conventional tablets. The technical challenge is protecting rabeprazole from saliva and gastric acid while allowing rapid oral dispersion.

This approach may require:

• Taste-masking technology.
• Protected microgranules.
• Low-moisture excipients.
• A separate enteric barrier.
• Packaging with strong humidity protection.

Because changing the dosage form may require a 505(b)(2) pathway rather than a conventional ANDA, the regulatory and clinical cost is higher.

4. Improved stability through excipient and packaging control

A differentiated product can target longer shelf life, broader storage conditions or reduced dependence on specialized packaging. Opportunities include:

• Alternative alkaline stabilizers.
• Barrier film coatings.
• Desiccant-integrated bottles.
• High-barrier blister materials.
• Lower-moisture manufacturing.
• More stable enteric polymers.
• Optimized plasticizer systems.

A patent application is more credible when it links the excipient combination to a measurable technical result, such as reduced degradation, improved dissolution after storage or lower coating weight.

5. Combination therapy products

Rabeprazole is used in H. pylori eradication regimens. Combination packs containing a proton-pump inhibitor and antibiotics can improve regimen organization, but they face additional commercial and regulatory complexity. The opportunity depends on:

• Local treatment guidelines.
• Antibiotic resistance patterns.
• Pack configuration.
• Labeling requirements.
• Coordination of patent and regulatory rights for each component.

How strong is the AcipHex patent estate?

The original AcipHex estate is commercially weak as a barrier to ordinary generic rabeprazole. Its principal value was historically concentrated in the compound, salt and original delayed-release product.

A new entrant should distinguish between:

Estate component	Strength against ordinary generic entry
Original rabeprazole compound rights	Low, expired
Original AcipHex tablet rights	Low, generic competition established
Standard excipient combinations	Low unless narrowly claimed
Pediatric sprinkle formulation	Potentially moderate, product-specific
Novel delivery system	Potentially moderate to strong if claims are narrow and supported
Manufacturing process claims	Variable; depends on process overlap
Trade secrets and know-how	Often more commercially relevant than expired patents

The strongest defensible position is likely to combine formulation claims with process controls, stability data and a clearly defined patient or administration advantage.

Which companies are challenging or competing with AcipHex?

The U.S. market has generic rabeprazole suppliers rather than a single dominant challenger. Generic competition can include manufacturers that sell directly, operate through authorized distributors or supply private-label products.

Competitive factors include:

• FDA approval of the specific strength.
• Therapeutic-equivalence rating.
• Manufacturing reliability.
• Wholesaler access.
• Reimbursement status.
• Ability to supply shortages.
• Cost of active pharmaceutical ingredient.
• Packaging and coating capacity.

Unlike a biologic, AcipHex has no biosimilar pathway. The relevant competitors are ANDA holders, authorized generics, private-label suppliers and potential 505(b)(2) developers.

What generic entry risks exist for a new rabeprazole product?

A new entrant faces limited originator patent risk but substantial commercial execution risk.

Risk	Probability for standard generic	Mitigation
Core patent blockage	Low	Confirm current Orange Book records
Bioequivalence failure	Moderate	Optimize acid-stage and buffer-stage dissolution
Stability failure	Moderate	Control alkalinity, moisture and packaging
Coating defects	Moderate	Use validated process parameters
Price erosion	High	Secure low-cost manufacturing
Supply interruption	Moderate	Qualify multiple excipient suppliers
Pediatric competition	Moderate	Differentiate administration and dose flexibility
505(b)(2) clinical burden	High for novel dosage forms	Limit claims or use established bridging data

What geographic coverage matters for AcipHex formulation rights?

U.S. patent expiration does not determine global freedom to operate. A commercial program should review:

• United States Orange Book listings.
• European patent and supplementary protection certificate records.
• Japanese patent and regulatory records.
• Canadian and Australian patent registers.
• National patents covering pediatric or formulation-specific products.
• Local pharmaceutical composition and process claims.

For an expired compound, geographic differentiation is more likely to matter for later formulation patents, trademarks, regulatory data rights and local manufacturing restrictions.

What litigation and settlement issues affect AcipHex?

The significant litigation history for rabeprazole was associated with generic entry and challenges to originator patents. That litigation is less important to ordinary U.S. tablet entry now that generic products are established.

For a new formulation, diligence should focus on:

• Patent infringement claims covering coating or multiparticulate architecture.
• ANDA litigation involving later-listed patents.
• Settlement agreements restricting launch dates or markets.
• Supply or licensing agreements involving rabeprazole API.
• Authorized-generic arrangements.
• Trademark restrictions on use of the AcipHex name.

No biosimilar litigation framework applies because rabeprazole is a synthetic small molecule.

Key Takeaways

• AcipHex is an established rabeprazole delayed-release product with expired core exclusivity.
• The commercial market is generic, not biologic, and entry generally proceeds through the ANDA pathway.
• Magnesium oxide, moisture control and enteric-polymer performance are central formulation variables.
• The best excipient opportunity is not a routine substitution. It is a documented improvement in stability, dissolution, coating efficiency or administration.
• Pediatric sprinkle and multiparticulate products offer stronger differentiation than another conventional tablet.
• Novel orally disintegrating or liquid products may require a 505(b)(2) strategy.
• Historic AcipHex patents are unlikely to block standard generic entry, but later formulation and process claims require product-specific review.
• Manufacturing know-how, coating yield, packaging and supply reliability may have greater commercial value than expired composition patents.

FAQs

Can magnesium oxide be replaced in a generic rabeprazole formulation?

Yes, but the replacement must support stability, dissolution and bioequivalence. A different alkalizing excipient can change microenvironmental pH, moisture response and drug release.

Is rabeprazole suitable for an orally disintegrating tablet?

Yes, but the product must protect the acid-labile active ingredient after oral dispersion. A protected multiparticulate system or enteric-coated granule is more technically suitable than exposing unprotected rabeprazole in the mouth.

Does AcipHex have biosimilar competition?

No. Rabeprazole is a synthetic small molecule. Competition occurs through generic drug applications, not biosimilar applications.

Can a new excipient combination support a rabeprazole patent?

It can if the claims define a novel and non-obvious combination with reproducible technical benefits. Mere substitution of a commonly used excipient is generally a weak basis for patent protection.

Is AcipHex Sprinkle a stronger commercial opportunity than standard rabeprazole tablets?

It can be. Sprinkle and multiparticulate products address swallowing limitations and pediatric administration, while standard tablets face mature generic competition and significant price pressure.

References

1. U.S. Food and Drug Administration. (1997). AcipHex (rabeprazole sodium) delayed-release tablets prescribing information. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (2016). AcipHex Sprinkle (rabeprazole sodium) delayed-release capsules prescribing information. FDA Drugs@FDA.

3. U.S. Food and Drug Administration. (2019). Inactive ingredient database. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.